Company Overview
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +115.98% |
| 6 Months: | -33.75% |
| 3 Months: | -11.92% |
| 1 Month: | -10.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 74.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EDSA Edesa Biotech, Inc. PHARMA | 4.73 | -2.75 | $45.60M | 0.00% | -63.54% | -122.93% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2013 | Mar 2014 | Jun 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.83K | 114.37K | 72.54K | 212.66K | 187.63K | 157.75K | 488.16K | 326.33K | 181.09K | 141.86K | 63.02K | 20.53K | 20.49K | 64.05K | 0 | 0 | 0 | 500 | 107.80K | 110.52K | 109.98K | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - | -1.31M | -1.10M | -1.19M | -1.41M | -1.15M | -1.29M | -1.39M | -1.34M | -421.99K | -405.74K | -540.78K | -1.32M | -1.11M | -1.52M | -1.77M | -2.61M | -9.51M | -6.07M | -5.16M | -4.58M | -5.80M | -2.38M | -2.41M | -2.06M | -1.86M | -2.22M | -1.93M | -1.90M | -1.64M | -1.90M | -2.34M | -4.30M |
| Net Income | -5.58M | -1.43M | 3.41M | -1.34M | -426.16K | 463.99K | -1.63M | -861.01K | -1.19M | -1.49M | -1.10M | -1.22M | -1.40M | -1.35M | -411.84K | -364.85K | -528.83K | -1.29M | -1.09M | -1.49M | -1.77M | -2.64M | -2.26M | -4.76M | -4.38M | -4.57M | -5.79M | -2.33M | -2.33M | -1.98M | -1.68M | -1.86M | -1.67M | -1.62M | -1.59M | -1.75M | -2.25M | -4.22M |
| Diluted EPS | -0.08 | -0.02 | 0.04 | -0.02 | -0.01 | 0.05 | - | - | -0.14 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| R&D Expense | 548.23K | 733.10K | 543.23K | 418.82K | 281.58K | 129.71K | 288.85K | 309.06K | 470.10K | 460.87K | 329.37K | 536.17K | 631.03K | 493.87K | 298.22K | 257.39K | 111.70K | 502.93K | 528.00K | 502.81K | 1.14M | 1.38M | 7.98M | 4.46M | 3.95M | 3.04M | 4.55M | 1.36M | 1.46M | 1.03M | 704.46K | 1.18M | 897.30K | 1.02M | 484.31K | 939.07K | 1.12M | 2.77M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Aug 2012 | Aug 2013 | Aug 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 286.05K | 545.47K | 372.13K | 758.69K | 1.27M | 228.29K | 211.85K | 328.80K | 0 | - | - | - | - |
| Operating Income | - | - | -5.72M | -4.34M | -4.91M | -5.22M | -5.08M | -6.40M | -23.68M | -18.37M | -9.22M | -7.01M | -7.91M |
| Net Income | -5.53M | -14.50M | -8.44M | -2.84M | -5.03M | -5.03M | -5.04M | -6.36M | -13.34M | -17.55M | -8.37M | -6.17M | -7.19M |
| Diluted EPS | - | -2.81 | -1.11 | -0.36 | -0.57 | - | - | - | - | - | - | - | - |
| R&D Expense | 2.63M | 2.02M | 2.46M | 1.03M | 1.73M | 1.97M | 2.09M | 3.33M | 17.95M | 13.34M | 4.79M | 2.88M | 3.67M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Aug 2011 | Aug 2012 | Aug 2013 | Aug 2014 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Dec 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 8.51M | 14.47M | 14.83M | 10.39M | 12.94M | 7.72M | 11.78M | - | 5.72M | 10.76M | 14.58M | 11.58M | 8.89M | 3.81M | 13.53M |
| Total Equity | 3.44M | 902.16K | -2.20M | 7.70M | 10.46M | 8.01M | 12.31M | 7.40M | 11.29M | 3.21M | 5.26M | 6.63M | 13.06M | 9.39M | 7.05M | 1.98M | 12.45M |
| Cash & Equivalents | 4.15M | 999.00K | 7.86M | 8.42M | 8.77M | 3.96M | 7.42M | 4.57M | 4.23M | 3.37M | 5.03M | 7.21M | 7.84M | 7.09M | 5.40M | 1.00M | 10.80M |
| Total Liabilities | - | - | 10.71M | 6.77M | 4.36M | 2.38M | - | - | - | - | 461.63K | 1.65M | 1.53M | 2.18M | 1.84M | 1.83M | - |
| Current Liabilities | - | - | 3.87M | 1.42M | 672.17K | 2.38M | 623.64K | 320.95K | 493.38K | - | 461.63K | 1.53M | 1.46M | 2.14M | 1.82M | 1.83M | 1.08M |
Cash Flows (Annual)
Figures in USD.
| Metric | Aug 2012 | Aug 2013 | Aug 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -4.41M | -4.51M | -4.70M | -4.62M | -4.99M | - | -12.28M | -6.64M | -4.89M | -7.32M |
| Investing Cash Flow | - | - | - | 122.47K | 557.41K | 1.69M | -4.47M | 19.07K | -6.15K | -5.66K | 0 | - | - |
| Financing Cash Flow | - | - | - | 106.78K | 7.31M | 0 | 8.77M | 7.09M | - | 11.63M | 4.83M | 592.03K | 17.03M |
| Capital Expenditure | -78.34K | -9.54K | -279.06K | -274.59K | -402.27K | -302.73K | -382.81K | -4.86K | -6.15K | -5.66K | - | - | - |
| Free Cash Flow | - | - | - | -4.69M | -4.91M | -5.00M | -5.00M | -4.99M | - | -12.28M | -6.64M | -4.89M | -7.32M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -655.33K | -1.81M | -4.30M | 9.71M |
Ratios (Annual)
Figures in %.
| Metric | Aug 2012 | Aug 2013 | Aug 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -1,536.7% | -571.9% | -386.0% | -2,288.6% | -2,397.1% | -1,946.7% | - | - | - | - | - |
| Net Margin % | -1,932.9% | -2,657.5% | -2,267.9% | -374.7% | -395.2% | -2,203.7% | -2,378.6% | -1,935.3% | - | - | - | - | - |
| ROE % | -612.9% | 660.1% | -109.6% | -35.5% | -40.8% | -68.0% | -44.6% | -96.0% | -102.2% | -186.9% | -118.8% | -311.4% | -57.7% |
| ROCE % | - | - | -43.8% | -54.2% | -39.9% | -70.6% | -45.0% | -69.3% | -180.4% | -194.7% | -130.5% | -354.1% | -63.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Velan Capital Investment Management LP | 8.58% | 827.50K | $3.43M |
| 2 | Rubric Capital Management LP | 6.94% | 669.50K | $2.77M |
| 3 | Perceptive Advisors Llc | 5.84% | 563.24K | $2.33M |
| 4 | Millennium Management Llc | 5.83% | 561.75K | $2.33M |
| 5 | Stonepine Capital Management, LLC | 4.73% | 456.44K | $1.89M |
| 6 | Boxer Capital Management, LLC | 2.13% | 205.00K | $848.70K |
| 7 | Vanguard Capital Management LLC | 0.85% | 81.84K | $338.81K |
| 8 | Geode Capital Management, LLC | 0.84% | 80.88K | $334.84K |
| 9 | Jane Street Group, LLC | 0.75% | 72.47K | $300.00K |
| 10 | Vanguard Fiduciary Trust Co | 0.40% | 38.72K | $160.29K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EDSA
Edesa Biotech Stock Price Forecast. Should You Buy EDSA? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFBUOE1KX1ZsMGRqZlZkTmNZaEZULWhEUlNpT1BVYXNPWjdXcDdOSk4xbDlvWHppbGNYSWc0LTBYc0lJMXpyaVRycA?oc=5" target="_blank">Edesa Biotech Stock Price Forecast. Should You Buy EDSA?</a> &nb…
Edesa Biotech Stock Sinks After Fresh Capital Raise - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPdGtMeGJSLXhXS2RjVWk5TlNDMW1VcFVWUVVqbXctdGdiblhlTkcxZWlLSDc2eTBvYlkxTXFLaWU0VDFzbHhjU1I1ZVpvYjlWSmQ4R2JPZERLTm91a19EX3FHaWNMU29KdGR2aDVISkx2Y3EweTkzWGF1ejZleUJ6cU11UmNILVU0RFJidH…
$EDSA stock is down 20% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOWTQxZFk3ZzdSdzA1T3llUlVCUEpLZk5VdTNCdUVpTVh5eFRUMmI4QmVfOEsta1Z1ODhtNjVwVV9ndGNYR29pUGVfNmhnX1hlZGdYaFZ2QjA3QmJkV1lQc2l6VUZOdThhbWxhZXNndzdOa01HVTVKb0NXb0RTVWduZVBmU0xFTTNlM0paOE…
Edesa Starts Activating First Vitiligo Trial Sites as Enrollment Nears - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQMDBhSFpVNTBHUmlqbmFFVE1ZQVBwUWJQTE84VE5UNmhkSl9lcXVSUWtNWmN6RXpXRDNiTF9KMWJ4QmxJWjhkWlkwUi1KREdpSlFtaUVWYzROMllsUVlObmRuLUxOQ2dFQ3hrdHlYQXRHLUdGSjJNOVV0eGhoZ0Q0a2R5SmQzTEFUZlRWbU…
EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxNcmo4Y0U4dEV1MlVLZkdxcFNGdFRmczJYY2hZV285dVhKNS1Fdy1VV216bWU0LWZLV2lVOXV1Y2NqOHNyOVV3cnJ3MER5a3pJeDJfaW5BcUk1NU5ITTU2TWxjclJKY3lkY3NSTWt3eVpjdGIzVlVQQkJBaTJZVnMwa0ZTcHZJTVhZS19NVn…
Edesa Biotech stock surges on positive Phase 3 trial data - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPaUN2OTd4RVNxTU9vY1k4dktwaGNNUmYxeWphMlUwNTZmQWZDNk8wWTZaNFNZMGdaM0pvSUluOWtmYlJkSi1yeVhzbGpPYk1xaTZrQlU1QkVMWEMtbTNKLVg4TnRuYlczdkltQS1QbWhaY0hjd01VMDNwTGRRbDRGOUlxVWdHNUc4a0hzNG…
EDSA — Frequently Asked Questions
What is the current share price of Edesa Biotech, Inc. (EDSA)?
As of 2026-09-19 21:16 PDT, Edesa Biotech, Inc. (EDSA) trades at $4.73 on NasdaqCM. Its 52-week range is $0.80 to $18.28.
What is the market capitalisation of EDSA?
Edesa Biotech, Inc. (EDSA) has a market capitalisation of $45.60M on NasdaqCM.
What is the P/E ratio of EDSA?
EDSA trades at a trailing price-to-earnings (P/E) ratio of -2.75. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 115.12.
What is the return on equity (ROE) of EDSA?
EDSA has a return on equity (ROE) of -122.93%. Its return on capital employed (ROCE) is -63.54%.
Is EDSA a good stock to buy?
This page provides a data-driven analysis of Edesa Biotech, Inc. (EDSA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.